Sanara MedTech, Inc. (SMTI) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1207033,
    "name": "Sanara MedTech, Inc.",
    "stock_name": "Sanara MedTech, Inc.",
    "full_name": "Sanara MedTech, Inc.",
    "name_url": "stocks-analysis/sanara-medtech-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "21.80",
    "chg": 1.6,
    "chgp": "7.92%",
    "dir": 1,
    "prev_price": "20.20",
    "mcapval": "318.26",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US79957L1008",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "142.49 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sanara-medtech-inc-1207033-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Sanara MedTech, Inc. Hits New 52-Week Low at $18.90",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sanara-medtech-inc-hits-new-52-week-low-at-1890-3721498",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanaraMedTechIn_priceRelatedfactors_3721498.png",
        "date": "2025-11-21 15:46:12",
        "description": "Sanara MedTech, Inc. has reached a new 52-week low, reflecting a significant decline in its stock value over the past year. The company, with a market capitalization of USD 318 million, has faced financial challenges, including consecutive quarterly losses and a negative return on equity."
      },
      {
        "title": "Sanara MedTech Hits New 52-Week Low at $19.06 Amid Ongoing Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sanara-medtech-hits-new-52-week-low-at-1906-amid-ongoing-struggles-3718607",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanaraMedTechIn_priceRelatedfactors_3718607.png",
        "date": "2025-11-20 16:27:49",
        "description": "Sanara MedTech, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 318 million, has faced financial difficulties, including consecutive quarterly losses and a negative return on equity. Its financial metrics indicate ongoing challenges in the biotechnology sector."
      },
      {
        "title": "Sanara MedTech Hits 52-Week Low at $19.10 Amid Ongoing Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sanara-medtech-hits-52-week-low-at-1910-amid-ongoing-struggles-3701984",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanaraMedTechIn_priceRelatedfactors_3701984.png",
        "date": "2025-11-14 15:51:56",
        "description": "Sanara MedTech, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company, with a market capitalization of USD 318 million, has faced ongoing financial challenges, including consecutive quarterly losses and negative returns on equity and capital employed."
      },
      {
        "title": "Sanara MedTech Hits 52-Week Low at USD 21.07 Amid Ongoing Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sanara-medtech-hits-52-week-low-at-usd-2107-amid-ongoing-struggles-3698039",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/SanaraMedTechIn_priceRelatedfactors_3698039.png",
        "date": "2025-11-13 16:02:16",
        "description": "Sanara MedTech, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company, with a market capitalization of USD 318 million, has faced ongoing financial challenges, including consecutive quarterly losses and a negative return on equity, raising concerns about its operational efficiency."
      },
      {
        "title": "Sanara MedTech Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sanara-medtech-forms-golden-cross-signaling-potential-bullish-breakout-3617274",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SanaraMedTechIn_goldencross_3617274.png",
        "date": "2025-10-13 15:19:14",
        "description": "Sanara MedTech, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. Despite a recent decline and mixed technical indicators, the stock has shown growth over three and five years, suggesting possible recovery opportunities for investors as market reactions unfold."
      },
      {
        "title": "Is Sanara MedTech, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sanara-medtech-inc-technically-bullish-or-bearish-3545822",
        "imagepath": "",
        "date": "2025-09-20 19:19:26",
        "description": "As of 11 September 2025, the technical trend for Sanara MedTech, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD is bullish, while the monthly MACD is bearish. Bollinger Bands indicate bullishness on both weekly and monthly time frames. Moving averages show a mildly bearish trend on the daily chart. The KST is mildly bullish on both weekly and monthly charts, while Dow Theory shows a mildly bullish stance monthly but no trend weekly. The OBV is bearish monthly and shows no trend weekly. \n\nIn terms of performance, the stock has underperformed the S&P 500 over the 1-week, YTD, 1-year, 3-year, and 5-year periods, with returns of -1.81%, 4.34%, 11.35%, 11.74%, and 25.96% respectively, compared to the S&P 500's returns of 1.05%, 12.22%, 17.14%, 70.41%, and 96.61%...."
      },
      {
        "title": "Is Sanara MedTech, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sanara-medtech-inc-overvalued-or-undervalued-3542494",
        "imagepath": "",
        "date": "2025-09-20 17:54:08",
        "description": "As of 11 February 2019, the valuation grade for Sanara MedTech, Inc. moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued given its high Price to Book Value of 7.15 and negative EV to EBIT and EV to EBITDA ratios of -32.29 and -73.36, respectively. Additionally, the Return on Capital Employed (ROCE) stands at -14.81%, and the Return on Equity (ROE) is at -36.01%, further supporting the notion of overvaluation.\n\nIn comparison to its peers, CareDx, Inc. has a P/E ratio of -27.90 and EV to EBITDA of -27.82, while AngioDynamics, Inc. shows a P/E ratio of -24.69 and an EV to EBITDA of 226.06, both indicating a challenging environment for Sanara MedTech. The company's stock performance relative to the S&P 500 is not available, but the overall financial metrics suggest a concerning outlook for investors...."
      }
    ],
    "total": 12,
    "sid": "1207033",
    "stock_news_url": "https://www.marketsmojo.com/news/sanara-medtech-inc-1207033"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Sanara MedTech, Inc. Hits New 52-Week Low at $18.90

2025-11-21 15:46:12

Sanara MedTech, Inc. has reached a new 52-week low, reflecting a significant decline in its stock value over the past year. The company, with a market capitalization of USD 318 million, has faced financial challenges, including consecutive quarterly losses and a negative return on equity.

Sanara MedTech Hits New 52-Week Low at $19.06 Amid Ongoing Struggles

2025-11-20 16:27:49

Sanara MedTech, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 318 million, has faced financial difficulties, including consecutive quarterly losses and a negative return on equity. Its financial metrics indicate ongoing challenges in the biotechnology sector.

Sanara MedTech Hits 52-Week Low at $19.10 Amid Ongoing Struggles

2025-11-14 15:51:56

Sanara MedTech, Inc. has reached a new 52-week low, reflecting a difficult year marked by a significant stock price decline. The company, with a market capitalization of USD 318 million, has faced ongoing financial challenges, including consecutive quarterly losses and negative returns on equity and capital employed.

Sanara MedTech Hits 52-Week Low at USD 21.07 Amid Ongoing Struggles

2025-11-13 16:02:16

Sanara MedTech Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-13 15:19:14

Sanara MedTech, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. Despite a recent decline and mixed technical indicators, the stock has shown growth over three and five years, suggesting possible recovery opportunities for investors as market reactions unfold.

Is Sanara MedTech, Inc. technically bullish or bearish?

2025-09-20 19:19:26

As of 11 September 2025, the technical trend for Sanara MedTech, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD is bullish, while the monthly MACD is bearish. Bollinger Bands indicate bullishness on both weekly and monthly time frames. Moving averages show a mildly bearish trend on the daily chart. The KST is mildly bullish on both weekly and monthly charts, while Dow Theory shows a mildly bullish stance monthly but no trend weekly. The OBV is bearish monthly and shows no trend weekly. In terms of performance, the stock has underperformed the S&P 500 over the 1-week, YTD, 1-year, 3-year, and 5-year periods, with returns of -1.81%, 4.34%, 11.35%, 11.74%, and 25.96% respectively, compared to the S&P 500's returns of 1.05%, 12.22%, 17.14%, 70.41%, and 96.61%....

Is Sanara MedTech, Inc. overvalued or undervalued?

2025-09-20 17:54:08

As of 11 February 2019, the valuation grade for Sanara MedTech, Inc. moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued given its high Price to Book Value of 7.15 and negative EV to EBIT and EV to EBITDA ratios of -32.29 and -73.36, respectively. Additionally, the Return on Capital Employed (ROCE) stands at -14.81%, and the Return on Equity (ROE) is at -36.01%, further supporting the notion of overvaluation. In comparison to its peers, CareDx, Inc. has a P/E ratio of -27.90 and EV to EBITDA of -27.82, while AngioDynamics, Inc. shows a P/E ratio of -24.69 and an EV to EBITDA of 226.06, both indicating a challenging environment for Sanara MedTech. The company's stock performance relative to the S&P 500 is not available, but the overall financial metrics suggest a concerning outlook for investors....

View All News